Wednesday, July 8, 2026

biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB

Matinas BioPharma Holdings

Matinas BioPharma Holdings clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bedminster, USA HQ
2011 Founded
16 Employees
Public company Type
MTNB · NYSE Ticker
Company details
Status
Public
HQ
Bedminster, USA
Founded
2011
Employees
16
Programs
9
Drugs
5
Patents
8
Intelligence · Clinical Programs

Matinas BioPharma Holdings projects

2 ClinicalTrials.gov programs sponsored by Matinas BioPharma Holdings.

Matinas BioPharma Holdings has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MAT2203

    Matinas BioPharma Holdings

    Cryptococcal Meningitis

    phase 3 small molecule active

    2 trials
  2. Placebo

    Matinas BioPharma Holdings

    Severe Hypertriglyceridemia

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Matinas BioPharma Holdings have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.